Thomas Rinderknecht - Basilea Pharmaceutica Member of the Board of Directors
| BPMUF Stock | USD 44.45 0.00 0.00% |
Director
Dr. Thomas M. Rinderknecht resigned as Vice Chairman of the Board of Directors of Basilea Pharmaceutica Ltd effective as of April 18, 2018, a position he has held since April 21, 2016. He was Member of the Board of Directors of the Company from April 6, 2011. He has served as Chairman of the Corporationrationrate Governance Committee and Member of the Audit Committee at the Company. Dr. Rinderknecht is a senior partner at the law firm Badertscher Rechtsanwaelte AG, in Zurich and Zug. He currently serves as Member of the Board and the Audit Committee of Chocoladefabriken Lindt Spruengli AG as Chairman of the Canyon Pharmaceuticals Group of Companies, Spanset Inter AG, Wollerau, and Caveat Holding AG, Hergiswil as Vice Chairman of APR Applied Pharma Research SA, Balerna, and the Marquard Media Group. He also serves as Member of the Board of InSphero AG, Schlieren Twin Dolphins AG, Zug, ADC Therapeutics SA, Epalinges Hotel de la Paix SA, Geneva the jointly controlled Badertscher Rechtsanwaelte AG and Veritas Trust AGFundmaster AG Family Office Companies and the NorseSatComiJet Group of Companies. Until February 2016 he served as Chairman of Vecap VC Partners AG, Stansstad, and of FLH Brands AG, Zug
| Age | 63 |
| Professional Marks | Ph.D |
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Amos BarShalev | Protalix Biotherapeutics | 65 | |
| Chaloemphong Mahawanitwong | Ginkgo Bioworks Holdings | 42 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Ali Behbahani | Crispr Therapeutics AG | 40 | |
| Robert Hines | Ginkgo Bioworks Holdings | N/A | |
| Rudolph Nisi | Sellas Life Sciences | 83 | |
| Stephen Galliker | Sellas Life Sciences | 68 | |
| Philip Ranker | Moderna | 53 | |
| Margaret Hamburg | Alnylam Pharmaceuticals | 62 | |
| William Ashton | Sellas Life Sciences | 64 | |
| Michael Bonney | Alnylam Pharmaceuticals | 59 | |
| Gary Evans | Novavax | 59 | |
| James Barry | Eyepoint Pharmaceuticals | 56 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Yodfat Buchris | Protalix Biotherapeutics | 44 | |
| Amy Schulman | Alnylam Pharmaceuticals | 57 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Thinh Bui | Sellas Life Sciences | 52 | |
| Tom Woiwode | Crispr Therapeutics AG | 43 | |
| Ken Takanashi | Wave Life Sciences | 54 | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Rinderknecht, Member of the Board of Directors | ||
| Marc Engelhardt, Member of the Management, Chief Medical Officer | ||
| Martin Nicklasson, Chairman of the Board of Directors | ||
| Domenico Scala, Member of the Board of Directors | ||
| Guenter Ditzinger, CTO, Member of the Management Committee | ||
| Marc MD, Chief Officer | ||
| Barbara Zink, Head - Corporate Development | ||
| Nicole Onetto, Member of the Board of Directors | ||
| Heidi McDaid, Head of Global HR | ||
| Peer Schroder, Head Relations | ||
| Ingrid HeinzeKrauss, Member of the Management Committee, CTO | ||
| Dietrich Stber, Head Services | ||
| HansBeat Guertler, Member of the Board of Directors | ||
| Peer Schroeder, Head of Corporate Communications & Investor Relations | ||
| Lutz Wevelsiep, Head Affairs | ||
| Daniel Lew, Member of the Board of Directors | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Donato Spota, CFO | ||
| Achim Kaufhold, Member of the Management Committee, Chief Medical Officer | ||
| Ronald Scott, CEO | ||
| Alf Nicklasson, Member of the Board of Directors | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| Anne Stehlin, Member of the Management Board, Head of Global Quality Management | ||
| Thomas Werner, Member of the Board of Directors | ||
| Laurenz Kellenberger, Chief Scientific Officer | ||
| Steven Skolsky, Member of the Board of Directors |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Basilea Pharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Basilea Pharmaceutica's short interest history, or implied volatility extrapolated from Basilea Pharmaceutica options trading.
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
| 0.82 | CSLLY | CSL | PairCorr |
| 0.73 | CMXHF | CSL Limited | PairCorr |
| 0.69 | TLKMF | Telkom Indonesia Tbk | PairCorr |
| 0.68 | WXIBF | WuXi Biologics | PairCorr |
| 0.67 | TLK | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |